Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Merck Will Build Beijing R&D Center; Invest $1.5 Billion in China

publication date: Dec 6, 2011
Merck announced plans to build an Asia Research & Development headquarters in Beijing, which will be devoted to innovative drug discovery and development. The new initiative is part of a broader $1.5 billion investment in China R&D that Merck will make over the next five years. Merck said the investment has two goals: building its own capabilities and fostering relationships with outside researchers. It expects the center to provide new drugs and vaccines that meet global needs. More details....

Stock Symbol: (NYSE: MRK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital